Elysium, founded by Leonard Guarente, is on a mission is to translate critical scientific advancements in aging research into accessible health products and technologies. The current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. At present Elysium markets four products: Basis, Matter, Format, Signal, and Index. Although these products are categorized as supplements rather than pharmaceuticals, Elysium is setting up clinical trials to establish thieir safety and effectiveness. As of May 2023 Elysium has 18 clinical trials listed on clinicaltrials.gov.. This foundation allows Elysium to establish an approach to scientific discovery and customer support that enables the pursuit of lifelong health and wellness. This trial aims to evaluate sirtuin supplements to benefit elderly trauma patients (BES2T BET). It is a phase I, randomized, double-blind, placebo-controlled, single institutional pilot trial investigating the impact of nicotinamide riboside/pterstilbene (BasisTM) on functional recovery after traumatic fall in elderly . ClinicalTrials.gov Identifier: NCT03635411.